Research Topics
| Alan I GreenSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidoneAlan I Green
Commonwealth Research Center, Boston, MA, USA
Schizophr Res 60:81-5. 2003....
Treatment of schizophrenia and comorbid substance use disorderAlan I Green
Commonwealth Research Center, Harvard Medical School Department of Psychiatry, Boston, MA, USA
Curr Drug Targets CNS Neurol Disord 1:129-39. 2002..Studies of other agents, employed in the pharmacotherapy of alcohol and substance use disorders without schizophrenia, are currently underway in patients with schizophrenia and comorbid disorders...
Detection and management of comorbidity in patients with schizophreniaAlan I Green
Department of Psychiatry, Harvard Medical School, Commonwealth Research Center, Massachusetts Mental Health Center, 74 Fenwood Road, Boston, MA 02115, USA
Psychiatr Clin North Am 26:115-39. 2003....
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episodeDiana O Perkins
Department of Psychiatry, C.B.# 7160, University of North Carolina School of Medicine, Chapel Hill, 27599-7160, USA
Schizophr Res 83:53-63. 2006....
Substance abuse and schizophrenia: pharmacotherapeutic interventionAlan I Green
Department of Psychiatry, Dartmouth Medical School, Lebanon, NH 03756, USA
J Subst Abuse Treat 34:61-71. 2008..Further studies are required to establish a solid evidence base of best practices for the use of medications in these patients...
Schizophrenia and co-occurring substance use disorderAlan I Green
Department of Psychiatry, Dartmouth Medical School, Hanover, NH, USA
Am J Psychiatry 164:402-8. 2007
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidolAlan I Green
Commonwealth Research Center and the Massachusetts Mental Health Center, Harvard Medical School, 74 Fenwood Road, Boston, MA 02115, USA
Schizophr Res 66:125-35. 2004..We report on rates of co-occurring substance use disorders in patients within their first episode of schizophrenia-related psychosis from a multicenter, international treatment trial of olanzapine vs. haloperidol...
Raclopride lessens the ability of clozapine to suppress alcohol drinking in Syrian golden hamstersDavid T Chau
Department of Psychiatry, Dartmouth Medical School, Lebanon, NH 03576, USA
Neuropharmacology 61:646-52. 2011..These data suggest that clozapine may limit alcohol drinking in the golden hamster (and possibly in patients with schizophrenia) in part because of its weak blockade of the DA D2 receptor...
Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of SchizophreniaHenry A Nasrallah
Department of Psychiatry, University of Cincinnati College of Medicine, 260 Stetson St, Suite 3224, Cincinnati, OH 45267 0559, USA
J Clin Psychiatry 70:4-46. 2009..Summit faculty member opinion is compared with field survey results, and recommendations are made for future research...
Clozapine chronically suppresses alcohol drinking in Syrian golden hamstersDavid T Chau
Department of Psychiatry, Dartmouth Medical School, One Medical Center Drive, Lebanon, NH 03756, USA
Neuropharmacology 58:351-6. 2010....
Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disordersMary F Brunette
Department of Psychiatry, Dartmouth Medical School, New Hampshire Dartmouth Psychiatric Research Center, Concord, NH 03301, USA
Schizophr Bull 32:637-43. 2006..This research, however, could be biased by selection factors. Studying patients who are currently in substance abuse remission could control for level of motivation to stop using substances and other methodological confounds...
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorderCarla M Canuso
Commonwealth Research Center, Boston, MA 02115, USA
Psychiatry Res 111:11-20. 2002....
Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophreniaIgor Elman
Department of Psychiatry, McLean Hospital and Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
Psychopharmacology (Berl) 176:369-75. 2004..Several lines of evidence suggest that the pathophysiology of schizophrenia may be associated with altered noradrenergic and glucoregulatory function...
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidolJeffrey A Lieberman
Department of Psychiatry, University of North Carolina School of Medicine, NC 27599 7160, USA
Am J Psychiatry 160:1396-404. 2003..This study compared the acute and long-term effectiveness of haloperidol with that of olanzapine in patients with first-episode psychosis in a large, controlled clinical trial...
Clozapine reduces alcohol drinking in Syrian golden hamstersAlan I Green
Commonwealth Research Center, Massachusetts Mental Health Center, 74 Fenwood Road, Boston 02115, USA
Psychiatry Res 128:9-20. 2004..These data further suggest that clozapine may serve as a prototype for developing novel treatments for alcohol abuse...
Treatment of schizophrenia and comorbid substance abuse: pharmacologic approachesAlan I Green
Department of Psychiatry, Dartmouth Medical School, Hanover, NH 03756, USA
J Clin Psychiatry 67:31-5; quiz 36-7. 2006..The adjunctive use of naltrexone or other agents also may be helpful. Further research on the optimal pharmacologic approach to patients with dual diagnosis is needed...
Comorbid schizophrenia and substance abuseAlan I Green
Department of Psychiatry, Dartmouth Medical School, Hanover, NH, USA
J Clin Psychiatry 67:e08. 2006..The efficacy of possible treatments for comorbid schizophrenia and substance abuse are weighed, including typical and atypical antipsychotics and psychosocial interventions, and a list of possible adjunctive agents is provided...
Pharmacotherapy for schizophrenia and co-occurring substance use disordersDouglas L Noordsy
Department of Psychiatry, Dartmouth Medical School, One Medical Center Drive, Lebanon, NH 03756, USA
Curr Psychiatry Rep 5:340-6. 2003....
Current research on co-occurring substance-use disorder in schizophreniaRobert E Drake
Psychiatric Research Center, Department of Psychiatry, Dartmouth Medical School, 2 Whipple Place, Lebanon, NH 03766, USA
Schizophr Bull 32:616-7. 2006
Pharmacotherapy for schizophrenia and co-occurring substance use disordersAlan I Green
Department of Psychiatry, Dartmouth Medical School DHMC, One Medical Center Drive, Lebanon, NH 03756 0001, USA
Neurotox Res 11:33-40. 2007..Ultimately, any medication given to these patients will need to be prescribed within psychosocial treatment programs aimed at assisting these patients in limiting and ultimately ceasing substance use...
Glucose effects on cognition in schizophreniaWilliam S Stone
Department of Psychiatry at Massachusetts Mental Health Center MMHC, Harvard Medical School, 74 Fenwood Road, Boston, MA 02115, USA
Schizophr Res 62:93-103. 2003..They also highlight the need to explore the extent to which glucose modulates nonmemory cognitive functions such as attention, and to understand more generally how glucose availability and regulation influence cognition...
Schizophrenia and comorbid substance use disorder: effects of antipsychoticsAlan I Green
Department of Psychiatry, Dartmouth Medical School, Lebanon, NH 03756, USA
J Clin Psychiatry 66:21-6. 2005..Further research is required, but early evidence suggests that at least some atypical antipsychotics may prove to be therapeutically effective in the treatment of patients with schizophrenia and comorbid substance use disorder...
Developing and testing adaptive treatment strategies using substance-induced psychosis as an exampleRee Dawson
Frontier Science and Technology Research Foundation, Boston, MA, USA
Psychopharmacol Bull 41:51-67. 2008..The intent is to explore the strengths and limitations of the methodological approach through a meaningful clinical example, with an emphasis on concepts and issues. Both methodology and clinical science are overviewed...
Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?Robert M Roth
Department of Psychiatry, Dartmouth Medical School DHMC, Lebanon, NH 03756, USA
Curr Psychiatry Rep 7:283-91. 2005..We propose that effective treatments may in part work through the modulation of brain reward circuitry dysfunction...
Comorbid psychiatric and substance abuse disorders: recent treatment researchPaula Riggs
Department of Psychiatry, University of Colorado Health Science Cneter, Denver, CO 80224, USA
Subst Abus 29:51-63. 2008..Treatment of ADHD and substance use disorders in adults; 3. Effects of substance abuse on the onset, severity, and treatment of schizophrenia. Recommendations for further research will be presented...
Clozapine-induced myocarditis: role of catecholamines in a murine modelJu Feng Wang
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
Eur J Pharmacol 592:123-7. 2008..Our data suggest that a beta-adrenergic blocking agent may be effective in reducing the incidence and severity of clozapine-induced myocarditis...
Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placeboIgor Elman
Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
Neuropsychopharmacology 27:293-300. 2002..Our data suggest that both risperidone and clozapine elevate plasma NE levels via enhanced neurotransmitter spillover, with risperidone producing a smaller effect...
The neural circuitry of reward and its relevance to psychiatric disordersDavid T Chau
Department of Psychiatry, Dartmouth Medical School, Dartmouth Health and Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
Curr Psychiatry Rep 6:391-9. 2004....
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patientsLarry Alphs
Schizophr Bull 30:577-86. 2004..Because of the complexity of the design issues, a steering committee, suicide monitoring board, and publication committee were established to assist with their management...
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)Herbert Y Meltzer
Psychiatric Hospital at Vanderbilt, 1601 23rd Ave S, Suite 306, Nashville, TN 37212, USA
Arch Gen Psychiatry 60:82-91. 2003..Approximately 50% of patients with schizophrenia or schizoaffective disorder attempt suicide, and approximately 10% die of suicide. Study results suggest that clozapine therapy significantly reduces suicidal behavior in these patients...
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidolRobert B Zipursky
Schizophrenia Programme, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
Br J Psychiatry 187:537-43. 2005..Substantial weight gain is common with many atypical antipsychotics...
Enhancing validity in co-occurring disorders treatment researchGregory J McHugo
Dartmouth Psychiatric Research Center, 2 Whipple Place, Suite 202, Lebanon, NH 03766, USA
Schizophr Bull 32:655-65. 2006..The central recommendation is to move rapidly from efficacy studies to more credible and valid effectiveness studies, in order to facilitate the adoption of evidence-based interventions in routine practice settings...
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episodeStephen M Strakowski
Center for Imaging Research and Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, 231 Albert Sabin Way ML0583, Cincinnati, OH 45267 0583, USA
Schizophr Res 78:161-9. 2005..This improvement is particularly relevant early in the course of schizophrenia...
Clozapine action on auditory P3 response in schizophreniaMargaret A Niznikiewicz
Schizophr Res 76:119-21. 2005
Antipsychotic drug effects on brain morphology in first-episode psychosisJeffrey A Lieberman
Departments of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Arch Gen Psychiatry 62:361-70. 2005..This raises the possibility that antipsychotics might alter such pathomorphologic progression in early-stage schizophrenia...
Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendationsDouglas M Ziedonis
University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, 675 Hoes Lane, Rm. D-349, Piscataway, NJ 08854, USA
J Psychiatr Pract 11:315-39. 2005..An algorithm summarizing the consensus recommendations is provided in an appendix...
Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorderEduardo Dunayevich
Outcomes Research, Eli Lilly and Co, Indianapolis, IN, USA
J Clin Psychiatry 68:1163-71. 2007..This study examines whether longer time to all-cause medication discontinuation is also linked to better functional outcomes...
Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidityCharlene E Le Fauve
Division of Clinical and Prevention Research, Treatment Research Branch, NIAAA, Bethesda, Maryland, USA
Alcohol Clin Exp Res 28:302-12. 2004..The panel focused on social anxiety disorder, depression, bipolar disorder, and schizophrenia...
